How inspectors review PV for ATMPs, vaccines and gene therapies How inspectors review PV for ATMPs, vaccines and gene therapies Understanding Pharmacovigilance (PV) for Advanced Therapy Medicinal Products (ATMPs), Vaccines, and Gene Therapies Pharmacovigilance (PV) is a critical component of the drug lifecycle, particularly for Advanced Therapy Medicinal Products (ATMPs), vaccines, and gene therapies. The regulatory landscape for these products is characterized by their complexity and the unique safety profiles they present. This tutorial provides an in-depth overview of how inspectors review Pharmacovigilance systems and practices in compliance with FDA regulations, as well as relevant considerations for the UK and…

Governance for Cross Functional Oversight of High Risk Specialty Product PV Governance for Cross Functional Oversight of High Risk Specialty Product PV Pharmacovigilance (PV) is a critical component in ensuring patient safety and effective product lifecycle management. For high-risk specialty products such as biosimilars, vaccines, and advanced therapy medicinal products (ATMPs), robust governance structures are essential for effective cross-functional oversight. This article aims to provide a comprehensive, step-by-step regulatory tutorial on establishing such governance frameworks, with a particular focus on the U.S. Food and Drug Administration (FDA) requirements and a comparative view of EU/UK regulations. Understanding the Regulatory Landscape for…

Periodic Reporting Requirements for Vaccines, ATMPs, and Biosimilars Understanding Periodic Reporting Requirements for Vaccines, ATMPs, and Biosimilars Pharmacovigilance is an essential component of drug and biological product safety, particularly for complex therapies such as vaccines, Advanced Therapy Medicinal Products (ATMPs), and biosimilars. Regulatory expectations regarding periodic reporting are pivotal for maintaining compliance and ensuring patient safety. This article provides a comprehensive step-by-step guide to understanding and implementing the reporting requirements mandated by the US FDA, with comparisons to EU and UK regulations where relevant. 1. Introduction to Pharmacovigilance Requirements Pharmacovigilance encompasses all activities aimed at monitoring the safety of medicinal…

Training HCPs and Sites on AE Reporting for Novel and Complex Products Pharmacovigilance (PV) is a critical component of drug safety that ensures the evaluation, monitoring, and prevention of adverse events associated with pharmaceutical products. This is particularly important for novel and complex products such as biosimilars, vaccines, advanced therapy medicinal products (ATMPs), and specialty products that may carry unique safety concerns. Training healthcare professionals (HCPs) and clinical trial sites on adverse event (AE) reporting is essential to maintain patient safety and regulatory compliance. This tutorial outlines the step-by-step approach to effectively train these stakeholders on AE reporting in accordance…

Principles of Plain Language Safety Communication for Complex Risk Messages Effective communication of safety information is a critical element of pharmacovigilance and post-market compliance. As pharmaceutical and biotech companies navigate the complexities of risk messages, the incorporation of plain language principles can significantly enhance the clarity and effectiveness of these communications. This article provides a structured, step-by-step tutorial on best practices for benefit-risk communication, with a focus on Direct Healthcare Professional Communications (DHPCs) and safety-related label updates. Understanding Benefit-Risk Communication Benefit-risk communication is essential in the pharmaceutical industry to ensure that healthcare professionals (HCPs) and patients receive accurate and comprehensible…

How to coordinate global safety related labelling updates and CMC impacts How to Coordinate Global Safety Related Labelling Updates and CMC Impacts In today’s global pharmaceutical environment, efficient management of safety-related labelling updates and their corresponding chemistry, manufacturing, and controls (CMC) impacts is crucial for regulatory compliance and patient safety. This tutorial is designed for pharma professionals, regulatory affairs, and medical affairs personnel, providing a structured, step-by-step approach to coordinating these updates across various regions, including the US, UK, and EU. Understanding the Importance of Safety Related Labelling Updates Effective communication of safety information is a critical component of pharmacovigilance….

Label Change Workflows After New Safety Information or Signals Emerge The pharmaceutical landscape is continuously evolving, with safety information being a critical component of the benefit-risk communication between regulatory authorities, healthcare professionals (HCPs), and patients. When new safety information or signals arise, organizations must execute structured workflows for safety-related label updates. This article provides a comprehensive step-by-step tutorial on navigating label change workflows post-signal emergence, ensuring compliance with FDA regulations and incorporating best practices that also align with principles in the UK and EU markets. 1. Understanding the Regulatory Framework The first step in managing label change workflows is understanding…

Designing and Executing DHPCs and Safety Communications in the EU and UK Effective communication regarding safety concerns in pharmaceutical products is essential for safeguarding public health. In both the European Union (EU) and the United Kingdom (UK), maintaining compliance with regulatory requirements is critical for pharmaceutical companies. This article serves as a comprehensive guide aimed at professionals in the pharmaceutical industry, specifically targeting those involved in clinical operations, regulatory affairs, and medical affairs. We will delve into the intricacies of designing and executing Direct Healthcare Professional Communications (DHPCs) and safety communications, emphasizing the significance of benefit-risk communication and ensuring alignment…

Benefit Risk Communication Strategies for Regulators, HCPs, and Patients Benefit Risk Communication Strategies for Regulators, HCPs, and Patients Effective communication of benefit-risk information is critical for regulatory authorities, healthcare professionals (HCPs), and patients involved in pharmaceuticals and biotechnology. With increasing scrutiny on drug safety and efficacy post-market authorization, the need for clear and actionable benefit-risk communication is paramount. This tutorial aims to navigate the intricacies of benefit-risk communication strategies, particularly focusing on regulated communications such as Direct Healthcare Professional Communications (DHPCs) and safety-related label updates. Our goal is to equip professionals in regulatory affairs, clinical operations, and medical affairs with…

Measuring Effectiveness of Safety Communications and DHPC Campaigns Measuring Effectiveness of Safety Communications and DHPC Campaigns In the fast-evolving sphere of pharmaceutical regulations, the effective communication of safety-related information is paramount. This is particularly critical for Drug and Health Product Communications (DHPCs) and safety-related label updates. Effective benefit-risk communication is essential for ensuring that healthcare professionals (HCPs) and patients understand the risks and benefits associated with medications. This article serves as a step-by-step tutorial aimed at professionals in clinical operations, regulatory affairs, and medical affairs, guiding them through the processes necessary to measure the effectiveness of safety communications. 1. Understanding…